FIELD: biotechnology.
SUBSTANCE: options of a method for diagnosing multiple sclerosis (hereinafter – MS) in a subject are proposed. The method includes incubation of a subject sample with protein related to DNA replication (hereinafter – Rep protein), or with anti-Rep antibodies, with subsequent quantitative determination of a forming immunological complex of anti-Rep antibodies with Rep protein. The amount of the specified complex in the subject sample, increased by at least 2 times compared to the amount in a reference sample indicates the presence of MS. In addition, hybridomas are proposed for producing antibodies binding with Rep protein. Antibodies produced by the specified hybridomas are used for the screening analysis of the subject sample for Rep protein.
EFFECT: invention provides for a platform for pathogen-specific diagnostic screening analyzes using Rep protein as an antigen.
15 cl, 8 dwg, 2 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMPROVED REP PROTEIN FOR USE IN DIAGNOSTIC ANALYZES | 2018 |
|
RU2736275C1 |
| HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| FUSION PROTEIN COMPRISING IL-2 PROTEIN AND CD80 PROTEIN AND ITS USE | 2019 |
|
RU2811541C2 |
| CD131-BINDING PROTEINS AND THEIR APPLICATIONS | 2016 |
|
RU2773927C2 |
| ANTIBODIES AGAINST SIGNAL-REGULATORY ALPHA PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2771964C2 |
| FUSION PROTEIN | 2016 |
|
RU2748643C2 |
| BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY | 2019 |
|
RU2756899C1 |
| POLYPEPTIDES THAT BIND TO THE C5 COMPONENT OR TO SERUM ALBUMIN AND THEIR FUSION PROTEINS | 2018 |
|
RU2794359C2 |
| STABLE COMPOSITIONS OF ANTI-TIGIT ANTIBODIES, INDIVIDUALLY AND IN COMBINATION WITH ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1), AND METHODS OF THEIR USE | 2018 |
|
RU2820576C2 |
